BACKGROUND: The recurrence rate of non-muscle invasive bladder cancer (NMIBC) is high, despite intravesical treatments. Importantly, patients are frequently unfit or unwilling to undergo a recommended radical cystectomy when standard intravesical treatments fail, due to the substantial risk of morbidity and mortality. For these patients, radiofrequency-induced hyperthermia combined with intravesical chemotherapy (RF-CHT) has shown promising results. We aim to determine treatment outcomes and assess the effect of (ablative) dose. METHODS: 299 intensively pretreated patients treated with RF-CHT were included in safety analysis. Of these, 274 patients who fulfilled induction treatments were included in efficacy analysis. Six-month complete response (CR) and durable response were reported for (concomitant) carcinoma in situ (CIS) patients and recurrence-free survival (RFS) for papillary patients. RESULTS: For CIS, six-month CR-rate was 56.0%; and durable response rates were 79.7%, 66.5%, and 40.3% at one-, two- and five-year, respectively. RFS rates for papillary patients were 77.9%, 57.5%, and 37.2%, respectively. Patients treated with ablative dose are less likely to develop recurrence (adjusted Hazard Ratio 0.54, p = 0.01), compared to adjuvant dose. CONCLUSIONS: RF-CHT is effective in NMIBC patients in whom standard intravesical treatments have failed and should be considered in patients who are unwilling or unfit to undergo radical cystectomy. Patients with CIS or residual papillary tumor at baseline benefit from ablative dose.
BACKGROUND: The recurrence rate of non-muscle invasive bladder cancer (NMIBC) is high, despite intravesical treatments. Importantly, patients are frequently unfit or unwilling to undergo a recommended radical cystectomy when standard intravesical treatments fail, due to the substantial risk of morbidity and mortality. For these patients, radiofrequency-induced hyperthermia combined with intravesical chemotherapy (RF-CHT) has shown promising results. We aim to determine treatment outcomes and assess the effect of (ablative) dose. METHODS: 299 intensively pretreated patients treated with RF-CHT were included in safety analysis. Of these, 274 patients who fulfilled induction treatments were included in efficacy analysis. Six-month complete response (CR) and durable response were reported for (concomitant) carcinoma in situ (CIS) patients and recurrence-free survival (RFS) for papillary patients. RESULTS: For CIS, six-month CR-rate was 56.0%; and durable response rates were 79.7%, 66.5%, and 40.3% at one-, two- and five-year, respectively. RFS rates for papillary patients were 77.9%, 57.5%, and 37.2%, respectively. Patients treated with ablative dose are less likely to develop recurrence (adjusted Hazard Ratio 0.54, p = 0.01), compared to adjuvant dose. CONCLUSIONS:RF-CHT is effective in NMIBC patients in whom standard intravesical treatments have failed and should be considered in patients who are unwilling or unfit to undergo radical cystectomy. Patients with CIS or residual papillary tumor at baseline benefit from ablative dose.
Authors: Wei Shen Tan; Anesh Panchal; Laura Buckley; Adam J Devall; Laurence S Loubière; Ann M Pope; Mark R Feneley; Jo Cresswell; Rami Issa; Hugh Mostafid; Sanjeev Madaan; Rupesh Bhatt; John McGrath; Vijay Sangar; T R Leyshon Griffiths; Toby Page; Dominic Hodgson; Shibendra N Datta; Lucinda J Billingham; John D Kelly Journal: Eur Urol Date: 2018-09-28 Impact factor: 20.096
Authors: Antoine G van der Heijden; Gerald Verhaegh; Cornelius F J Jansen; Jack A Schalken; J Alfred Witjes Journal: J Urol Date: 2005-04 Impact factor: 7.450
Authors: Samantha Cambier; Richard J Sylvester; Laurence Collette; Paolo Gontero; Maurizio A Brausi; George van Andel; Wim J Kirkels; Fernando Calais Da Silva; Willem Oosterlinck; Stephen Prescott; Ziya Kirkali; Philip H Powell; Theo M de Reijke; Levent Turkeri; Sandra Collette; Jorg Oddens Journal: Eur Urol Date: 2015-07-23 Impact factor: 20.096
Authors: Tom J H Arends; Ofer Nativ; Massimo Maffezzini; Ottavio de Cobelli; Giorgio Canepa; Fabrizio Verweij; Boaz Moskovitz; Antoine G van der Heijden; J Alfred Witjes Journal: Eur Urol Date: 2016-01-20 Impact factor: 20.096
Authors: F Johannes P van Valenberg; Antoine G van der Heijden; Rianne J M Lammers; Johannes Falke; Tom J H Arends; Egbert Oosterwijk; J Alfred Witjes Journal: Int J Hyperthermia Date: 2017-12-01 Impact factor: 3.914
Authors: Ryan L Steinberg; Lewis J Thomas; Nathan Brooks; Sarah L Mott; Andrew Vitale; Trafford Crump; Mounica Y Rao; Marcus J Daniels; Jonathan Wang; Supriya Nagaraju; William C DeWolf; Donald L Lamm; Max Kates; M Eric Hyndman; Ashish M Kamat; Trinity J Bivalacqua; Kenneth G Nepple; Michael A O'Donnell Journal: J Urol Date: 2019-12-10 Impact factor: 7.450
Authors: F Johannes P van Valenberg; Amir Kajtazovic; Giorgio Canepa; Gerson Lüdecke; Jill-Isabel Kilb; Katja K H Aben; Ofer Nativ; Sanjeev Madaan; Benjamin Ayres; Rami Issa; J Alfred Witjes Journal: Bladder Cancer Date: 2018-10-29
Authors: J W Van Hattum; E M Scutigliani; R F C P A Helderman; R Zweije; H M Rodermond; A L Oei; J Crezee; J R Oddens; T M De Reijke; P M Krawczyk Journal: Sci Rep Date: 2022-04-29 Impact factor: 4.996